FindTrial
Sign In

Efficiency of a composite personalised care on functional outcome in early psychosis: A Prospective Randomised Controlled Trial

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-520573-39-00
Enrollment
500
Registered
2025-01-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ultra High Risk of psychosis and first episode psychosis

Brief summary

Global functioning will be assessed using the Personal and Social Performance Scale (PSP), determined reference period 3 to 4 months after the begning

Interventions

DRUGFOLINORAL 25 mg
DRUGgélule
DRUGOmacor 1000 mg capsules molles
DRUGMUCODRILL 600 mg SANS SUCRE
DRUGcomprimé effervescent édulcoré au sucralose
DRUGVITAMINE B12 GERDA 250 microgrammes
DRUGcomprimé sécable

Sponsors

Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Global functioning will be assessed using the Personal and Social Performance Scale (PSP), determined reference period 3 to 4 months after the begning—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026